1 decyl 3 methylimidazolium chloride

DMPC was purchased from Avanti Polar Lipids (Alabaster, AL). 1-butyl-3-methylimidazolium chloride [C₄mim]Cl, assay ≥ 98%, 1-octyl-3-methylimidazolium chloride [C₈mim]Cl, assay ≥ 97%, 1-decyl-3-methylimidazolium chloride [C₁₀mim]Cl, assay 96%, 1-Butyl-3-methylimidazolium tetrafluoroborate [C₄mim][BF₄], assay ≥ 97%, 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide [C₄mim][Tf₂N], assay ≥98%, were purchased from Sigma-Aldrich (Diegem, Belgium). A schematic of the chemicals used is given in Fig 1. A list including the CACs of the ionic liquids used can be found in S1 Table). Spectroscopic grade chloroform assay 99.3% (stabilized with about 0.6% ethanol) was obtained from Analar (Normapur). HEPES buffer (pH 7.4) consisting of 10 mM HEPES from Fisher Scientific (assay 99%) and 150 mM NaCl-from Sigma-Aldrich (assay ≥ 99.5%) was used for hydration of the dried lipids. The quantities of lipids to reach the desired mixture concentrations were determined gravimetrically using a Sartorius balance yielding a maximal mole fraction uncertainty of ± 0.002.

A collection of 80 kinase inhibitors (Tocriscreen kinase inhibitor Toolbox) was purchased from Tocris Bio-Techne AG (Zug, Switzerland). All kinase inhibitors were provided in DMSO at a concentration of 10 mM and stored in aliquots at −20 °C. The compounds 1-dodecyl-3-methylimidazolium iodide, 1-decyl-3-methylimidazolium chloride, 1,3-didecyl-2-methylimidazolium chloride, 1-hexyl-3-methylimidazolium iodide, 1-benzyl-3-methylimidazolium chloride, cycloheximide, rapamycin, chloroquine, brefeldin A, bafilomycin A1, and mifepristone were all purchased from Sigma-Aldrich (Buchs, Switzerland).